The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the high-stakes nature of the biotechnology sector, Ionis Pharmaceuticals shares plummeted approximately 24% following disappointing clinical trial results. The joint Phase 3 study conducted with AstraZeneca for the drug Wainua failed to meet its primary endpoints, as it did not demonstrate statistically significant improvement in reducing cardiovascular mortality for ATTR-CM patients. According to reports, this failure represents a major setback for the company's expansion plans in the cardiovascular treatment market.
These negative results come amid intensifying competition in the ATTR-CM treatment landscape, where Ionis competes with major players like Alnylam Pharmaceuticals, which previously reported positive data for its rival therapies. In response to the news, Needham lowered its price target for IONS from $105.00 to $86.00 while maintaining a Buy rating. Partner AstraZeneca (AZN) also saw its stock impacted, closing at $178.49 per market data on July 9, 2026.
Investors are now monitoring Ionis's ability to regain market confidence through its remaining pipeline, with IONS last recorded at $86.33 (close July 7, 2026) prior to the full pricing in of the trial data. Looking ahead, healthcare traders are awaiting any regulatory updates from the FDA, while broader markets focus on the U.S. Balance of Trade data on July 7, 2026, to gauge general sentiment toward growth stocks.